Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL2178826 | 0.89 | NAPRT (0.48) | NAPRTKDM4ETDP1MAPTL3MBTL1 | |
| SCHEMBL5676 | 0.80 | — | — | |
| Benzoic Acid SCHEMBL28439288 | 0.77 | NAPRT (0.61) | NAPRTKDM4EL3MBTL1ALDH1A1TSHR | |
| Carbamic Acid SCHEMBL5075379 | 0.77 | NAPRT (0.48) | NAPRTKDM4ETDP1MAPTL3MBTL1 | |
| SCHEMBL244401 | 0.76 | — | — | |
| Hydrogen Sulfide SCHEMBL27838627 | 0.76 | — | — | |
| Carbamic Acid SCHEMBL1413116 | 0.76 | HSP90AA1 (0.67) | NAPRTKDM4ETDP1MAPTL3MBTL1 | |
| SCHEMBL4259192 | 0.76 | HSP90AA1 (0.36) | NAPRTKDM4EL3MBTL1P2RX7 | |
| Carbamic Acid SCHEMBL21437196 | 0.74 | ALDH1A1 (0.50) | NAPRTKDM4ETDP1MAPTL3MBTL1 | |
| 2-Aminopyridine SCHEMBL5693366 | 0.73 | NOS3 (0.73) | NAPRTKDM4ETDP1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025126151-A1 | METHODS FOR TREATING BREAST CANCER | NOVARTIS AG (CH) | 2025-06-19 | — | — | WO | disclosed |
| US-20250090567-A1 | 5-FU AND RNAOG COMBINED IMMUNOCHEMOTHERAPY FOR PANCREATIC CANCER TREATMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-03-20 | — | — | US | disclosed |
| US-20250064784-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHODS OF TREATMENT | SHAARE ZEDEK SCIENTIFIC LTD. (IL) | 2025-02-27 | — | — | US | disclosed |
| US-12171746-B2 | Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture | LIPOMEDIX PHARMACEUTICALS LTD. (IL) | 2024-12-24 | — | — | US | disclosed |
| US-20240366650-A1 | TREATMENT OF DRUG RESISTANT PROLIFERATIVE DISEASES WITH TELOMERASE MEDIATED TELOMERE ALTERING COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-07 | — | — | US | disclosed |
| US-12070472-B2 | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-08-27 | — | — | US | disclosed |
| EP-4382093-A1 | ORAL SUSPENSIONS COMPRISING CAPECITABINE | a Fine House S.A. (GR) | 2024-06-12 | — | — | EP | disclosed |
| US-20240158507-A1 | VISTA Antagonist and Methods of Use | DARTMOUTH COLLEGE (US) | 2024-05-16 | — | — | US | disclosed |
| CN-117844039-A | Molecularly imprinted polymer and preparation method and application thereof | 吉林大学 | 2024-04-09 | — | — | CN | disclosed |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| EP-1278518-A2 | A COMPOSITION COMPRISING CAMPTOTHECIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2003-01-29 | — | — | EP | disclosed |
| US-6503889-B2 | Especially capecitabine, gemcitabine, CPT-11 or pemetrexed | AVENTIS PHARMA S.A. (FR) | 2003-01-07 | — | — | US | disclosed |
| US-6469058-B1 | FOR THE TREATMENT OF NONSMALL CELL LUNG CANCER | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| EP-1115391-B1 | CHEMOTHERAPY OF CANCER WITH ACETYLDINALINE IN COMBINATION WITH GEMCITABINE, CAPECITABINE OR CISPLATIN | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002057239-A2 | PYRIMIDINE PHOSPHORYLASE AS A TARGET FOR IMAGING AND THERAPY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020091132-A1 | Composition and method comprising CPT-11 and a pyrimidine derivative for the treatment of cancer | AVENTIS PHARMA, S.A. | 2002-07-11 | — | — | US | disclosed |
| US-20020068743-A1 | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | PFIZER ENTERPRISES SARL (LU) | 2002-06-06 | — | — | US | disclosed |
| WO-2001062235-A2 | A COMPOSITION COMPRISING CAMPTOTHECIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2001-08-30 | — | — | WO | disclosed |
| EP-1115391-A1 | CHEMOTHERAPY OF CANCER WITH ACETYLDINALINE IN COMBINATION WITH GEMCITABINE, CAPECITABINE OR CISPLATIN | WARNER-LAMBERT COMPANY (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018393-A1 | CHEMOTHERAPY OF CANCER WITH ACETYLDINALINE IN COMBINATION WITH GEMCITABINE, CAPECITABINE OR CISPLATIN | WARNER-LAMBERT COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068743-A1 | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | TYMP, TOP1, DPYD | NAPRT 329/4885KDM4E 1631/4885TDP1 69/4885 |
| US-12171746-B2 | Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture | LIPC, MLEC, LPXN | NAPRT 2690/4885KDM4E 2512/4885TDP1 1594/4885 |
| US-20240366650-A1 | TREATMENT OF DRUG RESISTANT PROLIFERATIVE DISEASES WITH TELOMERASE MEDIATED TELOMERE ALTERING COMPOUNDS | TERT, POT1, TERF2 | NAPRT 472/4885KDM4E 1952/4885TDP1 14/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | NAPRT 103/4885KDM4E 3294/4885TDP1 323/4885 |
| US-12070472-B2 | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds | TERT, POT1, TERF2 | NAPRT 472/4885KDM4E 1952/4885TDP1 14/4885 |
| US-20250064784-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHODS OF TREATMENT | MLEC, LIPC, LPXN | NAPRT 2946/4885KDM4E 2606/4885TDP1 1465/4885 |
| US-20020091132-A1 | Composition and method comprising CPT-11 and a pyrimidine derivative for the treatment of cancer | TYMP, TOP1, DPYD | NAPRT 245/4885KDM4E 1890/4885TDP1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.